Page last updated: 2024-12-05

2,4-dichloroaniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-dichloroaniline is an organic compound with the formula C6H3Cl2NH2. It is a colorless to light-brown solid, and is a precursor to many commercial dyes, herbicides, and pharmaceuticals. It is synthesized by chlorination of aniline. 2,4-dichloroaniline is a known environmental contaminant. It can be toxic to aquatic life and may be carcinogenic. 2,4-dichloroaniline has been studied extensively because of its potential to cause health problems in humans and animals. It is important to understand the effects of this compound on the environment and human health so that we can take steps to protect ourselves and the planet.'

2,4-dichloroaniline: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,4-dichloroaniline : A dichloroaniline carrying chloro substituents at positions 2 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11123
CHEMBL ID1528820
CHEBI ID46635
SCHEMBL ID158279
MeSH IDM0154135

Synonyms (70)

Synonym
BIDD:ER0533
aniline, 2,4-dichloro-
1-amino-2,4-dichlorobenzene
2,4-dichlorobenzenamine
nsc-8756
wln: zr bg dg
2,4-dichloranilin
2,4-dichloroaniline
nsc8756
554-00-7
inchi=1/c6h5cl2n/c7-4-1-2-6(9)5(8)3-4/h1-3h,9h
benzenamine, 2,4-dichloro-
NCGC00091375-01
2,4-dca
brn 0386422
nsc 8756
ccris 6012
hsdb 5428
einecs 209-057-8
2,4-dichloranilin [german]
o,p-dichloroaniline
CHEBI:46635 ,
2,4-dichlorophenylamine
2,4-dichloroaniline, 99%
NCGC00091375-02
2,4-dichloroaniline, >=97.0% (gc)
D0321
AKOS000118881
NCGC00091375-03
dtxsid1024966 ,
tox21_303206
NCGC00257110-01
cas-554-00-7
dtxcid404966
NCGC00259072-01
tox21_201522
A830623
2,4-bis(chloranyl)aniline
2,4-dichloro aniline
2,4-dichlorobenzene aniline
STL168887
2,4-dichloro-phenylamine
4-12-00-01241 (beilstein handbook reference)
ec 209-057-8
unii-19ae42m6ws
19ae42m6ws ,
FT-0610035
PS-6249
dichloroaniline, 2,4-
2,4-dichloroaniline [hsdb]
RP10174
SCHEMBL158279
Z57127562
2,4-dichloro-aniline
2,4-di-chloroaniline
2,4-dichloraniline
2,4-dichloroanilin
AC-10180
AM87064
W-105564
CHEMBL1528820
mfcd00007661
F2190-0455
2,4-dichloroaniline, pestanal(r), analytical standard
2,4-dichloroaniline 100 microg/ml in methanol
2,4dichloro aniline
2,4-dichloroaniline, pract.
Q3102438
EN300-18059
CCG-302558

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A dose-response was evidenced in both approaches, however the in vivo exposures appeared to be approximately two orders of magnitude more sensitive than the in vitro exposures."( Rainbow trout primary epidermal cell proliferation as an indicator of aquatic toxicity: an in vitro/in vivo exposure comparison.
Fitzgerald, R; Kilemade, M; Lyons-Alcantara, M; Mothersill, C; Rose, T, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dichloroaniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency27.02860.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency44.66840.000221.22318,912.5098AID588515
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency45.99090.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency44.66840.000817.505159.3239AID588544
farnesoid X nuclear receptorHomo sapiens (human)Potency0.21870.375827.485161.6524AID743220
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency67.89270.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency53.92910.001628.015177.1139AID1224843
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.057019.739145.978464.9432AID1159509
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency54.48270.000627.21521,122.0200AID651741
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (11.54)18.7374
1990's5 (19.23)18.2507
2000's13 (50.00)29.6817
2010's5 (19.23)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.38 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index39.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.85%)4.05%
Observational0 (0.00%)0.25%
Other25 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]